BridgeBio Pharma (BBIO) Financial Analysis & Valuation | Quarter Chart
BridgeBio Pharma (BBIO)
BBIOPrice: $61.8
Fair Value: 🔒
🔒score
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs inc... more
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for ... more
Description
Shares
| Market Cap | $11.77B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Neil Kumar |
| IPO Date | 2019-06-27 | CAGR | — |
| Employees | 725 | Website | www.bridgebio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.45% | Total Yield | 0.45% |
BBIO chart loading...
Fundamentals
Technicals
| Enterprise Value | $9.84B | P/E Ratio | -14.68 |
| Forward P/E | 36575 | PEG Ratio | — |
| P/S Ratio | 50.61 | P/B Ratio | -6.67 |
| P/CF Ratio | -18.14 | P/FCF Ratio | -17.94 |
| EPS | $-4.21 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 7.62% | Gross Margin | 0.97% |
| Operating Margin | -2.78% | Profit Margin | -3.29% |
| ROE | 0.51% | ROA | -0.72% |
| ROCE | -0.72% | Current Ratio | 5.19 |
| Quick Ratio | 5.08 | Cash Ratio | 4.26 |
| Debt/Equity | -1.5 | Interest Coverage | -4.94 |
| Altman Z Score | -3.28 | Piotroski Score | 3 |